Author:
Icli F,Akbulut H,Uner A,Yalcin B,Baltali E,Altinbas M,Coşkun Ş,Komurcu S,Erkisi M,Demirkazik A,Senler F C,Sencan O,Büyükcelik A,Boruban C,Onur H,Zengin N,Sak S D
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA (1995) Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute referral center. J Clin Oncol 13: 2056–2065
2. Athanassiades P, Bacoyiannes H, Kontoyiannes D (1986) Etoposide and cisdichlorodiammine platinum in advanced breast carcinoma resistant to previous chemotherapy. Chemioterapia 5: 125–127
3. Atienza DM, Vogel CL, Trock B, Swain SM (1995) Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 12: 2485–2490
4. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210–1215
5. Bontenbal M, Planting AS, Verweij J, de Wit R, Kruit WH, Stoter G, Klijn JG (1995) Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res Treat 34: 185–189
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献